Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia

CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective in refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL). This review focuses on achievements, current obstacles, and future directions in CAR-T research. A high complete remission rate of 68% to 93% could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xian, Li, Jing-Jing, Lu, Pei-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046249/
https://www.ncbi.nlm.nih.gov/pubmed/31977556
http://dx.doi.org/10.1097/CM9.0000000000000638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046249/
https://www.ncbi.nlm.nih.gov/pubmed/31977556
http://dx.doi.org/10.1097/CM9.0000000000000638

Ejemplares similares